Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

OK

IES 29 June 2022 Virtual Seminar 9:30-11:00 AM ET

Cross-evolutionary and cross-species eosinophils
29 June
9:30-11:00 am ET

June Seminar Registration

Cross-species and cross-evolutionary considerations in eosinophil biology

Steven J. Ackerman, PhD
Professor of Biochemistry and Molecular Genetics, and Medicine, University of Illinois at Chicago



 Dr. Ackerman has > 35 years' experience on the roles of innate immune cells, mainly eosinophils, in host immune responses and pathogenesis of parasitic, allergic and gastrointestinal diseases,   focused on asthma and eosinophilic esophagitis (EoE). He has a world-class reputation performing   seminal basic studies defining eosinophil protein biochemistry, structural biology, cellular and   molecular biology, including mechanisms that regulate eosinophil gene transcription and   development, roles of eosinophil-fibroblast interactions in fibrogenesis in eosinophil-associated   diseases, and mechanisms that regulate eosinophil-mediated tissue remodeling and fibrosis.   Recent clinical/translational research include co-development of the Esophageal String Test for   minimally invasive monitoring of disease status in EoE, and development of novel peptide   nanoparticle biased antagonists targeting CCR3 that block eosinophil recruitment into tissues.


 

 

Eosinophil depletion in humans: an update

Amy Klion, MD
Chief, Human Eosinophil Section Laboratory of Parasitic Diseases National Institute of Allergy and Infectious Diseases














 

 

Considerations of Eosinophil Biology and Functions in Mouse Models of Human Disease and Health

Elizabeth A. Jacobsen, PhD
Assistant Professor in the Division of Allergy, Asthma and Clinical Immunology, Department of Immunology, Mayo Clinic Arizona



Dr. Elizabeth (Beth) Jacobsen has greater than 17 years of expertise on the functions of eosinophils in   mouse models of asthma and other models of inflammatory diseases. Her early findings showed that   eosinophils can recruit, activate, and polarize immune cells in translational models of asthma and that   eosinophil-derived IL-13 is critical to specific lung pathologies. Through this work she contributed and   collaborated on the LIAR hypothesis generated by the late Dr. James J. Lee, which states that   eosinophils regulate the local immunity and/or remodeling/repair in disease and physiological   homeostasis.  Currently, Dr. Jacobsen’s research has the goal of expanding our understanding the   immune activation states of eosinophils and the factors that regulate these immune phenotype   transitions in eosinophils. Moreover, she is an expert on eosinophil-specific strains of mice and   reagents  for the identification of eosinophils and their granule proteins in both mice and humans.  As a   result of this expertise and research, she has extensive collaborations to study eosinophils in diseases   such as lung allograft rejection, liver injury, metabolic disease, and cancer. In summary, she has been   invited to write book chapters, review articles, and consult on eosinophil biology for both at academic  and pharmaceutical institutions

 


Corporate Advisory Council

Amgen             AstraZeneca             GSK